9MW4113 (dupilumab biosimilar)
/ Mabwell (Shanghai) Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 28, 2026
A Phase I Study of 9MW4113 Injection Versus Dupixent
(clinicaltrials.gov)
- P1 | N=208 | Active, not recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
New P1 trial
1 to 1
Of
1
Go to page
1